PIM447, Ruxolitinib (INC424), LEE011 (# 605)
Laufzeit: 01.01.2018 - 31.12.2020
imported
Kurzfassung
A phase Ib, multi-center, open-label, dose-escalation study
of PIM447 in combination with ruxolitinib (INC424) and
LEE011 administered orally in patients with myelofibrosis
